What is the official website of Sanofi Belgium ?

The official website of Sanofi Belgium is http://www.sanofi.be.

What is Sanofi Belgium's cybersecurity risk score?

Sanofi Belgium has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sanofi Belgium experienced?

According to Rankiteo, Sanofi Belgium currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sanofi Belgium been affected by any supply chain cyber incidents ?

According to Rankiteo, Sanofi Belgium has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sanofi Belgium have SOC 2 Type 1 certification ?

According to Rankiteo, Sanofi Belgium is not certified under SOC 2 Type 1.

Does Sanofi Belgium have SOC 2 Type 2 certification ?

According to Rankiteo, Sanofi Belgium does not hold a SOC 2 Type 2 certification.

Does Sanofi Belgium comply with GDPR ?

According to Rankiteo, Sanofi Belgium is not listed as GDPR compliant.

Does Sanofi Belgium have PCI DSS certification ?

According to Rankiteo, Sanofi Belgium does not currently maintain PCI DSS compliance.

Does Sanofi Belgium comply with HIPAA ?

According to Rankiteo, Sanofi Belgium is not compliant with HIPAA regulations.

Does Sanofi Belgium have ISO 27001 certification ?

According to Rankiteo,Sanofi Belgium is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sanofi Belgium operate in ?

Sanofi Belgium operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sanofi Belgium have ?

Sanofi Belgium employs approximately 261 people worldwide.

Does Sanofi Belgium own any subsidiaries ?

Sanofi Belgium presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sanofi Belgium have ?

Sanofi Belgium's official LinkedIn profile has approximately 15,901 followers.

What is the NAICS classification code for Sanofi Belgium ?

Sanofi Belgium is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sanofi Belgium have a Crunchbase profile ?

No, Sanofi Belgium does not have a profile on Crunchbase.

Does Sanofi Belgium have a LinkedIn profile ?

Yes, Sanofi Belgium maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sanofi-belgium.

How many cybersecurity incidents has Sanofi Belgium experienced ?

As of August 13, 2026, Rankiteo reports that Sanofi Belgium has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sanofi Belgium have ?

Sanofi Belgium has an estimated 5,728 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sanofi Belgium

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Sanofi Belgium Vendor Cyber Rating & Cyber Score

sanofi.be

Add Your Compliance Badge

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. ➡ Do you have a disruptive healthcare solution? Sanofi Consumer Healthcare Open Innovation could be the right collaborative partner for you. If you have an asset that you are passionate about and you are looking to develop it in a partnership alliance, don't hesitate

Sanofi Belgium A.I CyberSecurity Scoring

Scoring History

Sanofi Belgium

Sanofi Belgium CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sanofi Belgium Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sanofi Belgium

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sanofi Belgium in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sanofi Belgium in 2026.

Incident Types Sanofi Belgium vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sanofi Belgium in 2026.

Incident History - Sanofi Belgium (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sanofi Belgium Subsidiaries

Sanofi Belgium

Pharmaceutical Manufacturing

Website: http://www.sanofi.be

Company Size: 261

SanofiPharmaceutical Manufacturing

MedleyPharmaceutical Manufacturing

Sanofi Pasteur MSDPharmaceutical Manufacturing

Southern Champion TrayManufacturing

Sanofi PolskaPharmaceutical Manufacturing

Foundation SHôpitaux et services de santé

Loading…

Sanofi Belgium Similar Companies

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

Sanofi Belgium CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 25, 2021 08:00 AM

Sanofi, Capgemini, Generali and Orange create a digital ecosystem dedicated to e-health

Paris (France) – 25 January 2021 – Sanofi, Capgemini, Generali and Orange announce plans to create a joint venture in France to fast-track the development...

Read Article

May 05, 2016 07:00 AM

Sanofi Biologics Plant Expansion, Geel, Belgium

French pharmaceutical company Sanofi is expanding its biologics plant in Geel, Belgium, to add to its manufacturing and commercial...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-71194

SUMMARY

In OpenStack Designate before 22.0.2, the mDNS handler performs pool-blind lookups when resolving record queries and NOTIFY requests. When two zones with the same name exist across different pools, the lookup fails with a deterministic error, causing the handler to return REFUSED for all DNS queries through that path. The _handle_notify path is exploitable via a single unauthenticated UDP packet. This is independently reachable through the cross-tenant zone overlap described in a different recent CVE, and also affects legitimate same-tenant cross-pool configurations. BIND9 views do not mitigate this issue as mDNS is a shared service upstream of any view configuration.

Published

Date2026-08-12

Updated

Date2026-08-12

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:N/A:H

Impact Score

Exploitability

2.2

REFERENCES

CVE-2026-71193

SUMMARY

In OpenStack Designate before 22.0.1, zone creation checks (_is_subzone, _is_superzone, and the duplicate-zone DB constraint) are scoped to the target pool only. An authenticated user can bypass these checks by scheduling a zone to a different pool via the AttributeFilter scheduler, creating an overlapping zone that conflicts with another tenant's zone. This enables cross-tenant DNS hijack (redirecting traffic to attacker-controlled IPs) and DNS denial of service (NODATA responses). Exploitation requires a multi-pool deployment with AttributeFilter enabled in scheduler_filters, which is a non-default but documented and supported configuration for self-service tiering.

Published

Date2026-08-12

Updated

Date2026-08-12

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:N/I:H/A:H

Impact Score

5.8

Exploitability

3.1

REFERENCES

CVE-2026-49481

SUMMARY

UpSnap is a wake on lan web app. Versions prior to 5.4.0 have an OS command injection vulnerability in the UpSnap’s device management functionality due to the presence of unsafe shell command template interpolation using the ip and the mac fields. User-controlled values can be inserted into the wake_cmd and shutdown_cmd templates and executed via /bin/sh -c (Linux) or cmd /C (Windows) without sanitization, resulting in an authenticated Remote Code Execution (RCE). A low-privileged user with permission to create or edit devices can execute arbitrary operating system commands on the UpSnap hosted server. Version 5.4.0 patches the issue.

Published

Date2026-08-12

Updated

Date2026-08-12

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:N

Impact Score

5.8

Exploitability

3.1

REFERENCES

CVE-2026-47718

SUMMARY

FUXA is a web-based Process Visualization (SCADA/HMI/Dashboard) software. When `secureEnabled=true`, FUXA `1.3.0-2773` still allows guest and invalid-token requests to read project, alarms, and scheduler APIs. Version 1.3.1 fixes this issue.

Published

Date2026-08-12

Updated

Date2026-08-12

RISK INFORMATION (Score: )

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-47717

SUMMARY

FUXA is a web-based Process Visualization (SCADA/HMI/Dashboard) software. In fuxa-server version 1.3.0, the GET /api/project endpoint exposes sensitive project configuration data to guest-context requests even when secureEnabled is enabled. Version 1.3.1 fixes the issue.

Published

Date2026-08-12

Updated

Date2026-08-12

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…